Diabetes Drugs and Cardio-renal Protection: Trials and Indications

November 25, 2019

Cardiovascular outcomes trials of diabetes drugs have led to label expansions and guideline endorsements. Do you recall the studies and the outcomes? Find out, here.

Recent FDA-mandated cardiovascular outcomes trials of the sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have revealed both cardio- and renal- protective properties in patient with type 2 diabetes. Based on these studies, several agents now carry expanded indications.In the following 5 questions on these studies and their outcomes, you will know the names of the drugs and the trials, but do you remember which study supports the labeling change for which drug? Find out, and good luck.